Replies to post #559396 on $Stock*Shop*Charts*News*Option$

[dDT]

Valeant Pharmaceuticals reports Q4 results

Valeant Pharmaceuticals (NYSE:VRX): Q4 EPS of $2.58
Revenue of $2.28B (+10.7% Y/Y)
Shares +1.15% PM.